Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : JMAR Technologies(JMAR) -- Ignore unavailable to you. Want to Upgrade?

To: Bridge Player who wrote (9660)	8/27/2007 5:46:50 PM
From: X-Ray Man	Respond to of 9695

From the JMAR news page posted 8-15-07 jmar.com Recently, there has been a surge of activity involving our BriteLight™ laser system. Most significant is the recent news of a system redesign to be used as a double pulse plasma laser for the detection of explosives and drugs. While this is extremely positive, it has caused shareholders to wonder what is happening with BioSentry, as there has not been any recent news. To reassure you that all is well and still progressing, here are several items of interest: JMAR currently has a BioSentry technician in the Netherlands installing a system at Interline/Vitens. As stated in the press release announcing the sale of the system, Vitens is the largest water company in The Netherlands, serving more than 5.4 million customers. This is the second installation of a BioSentry System in Europe this year. The EPA finished their initial testing and the system continues to operate at their facility 24/7 for long term evaluation. We have been told by the EPA that the final report will not be out until late 2007. All responses from the Agency regarding the testing and performance of the BioSentry have been highly positive. JMAR is preparing for an in-house demonstration of the BioSentry for a major pharmaceutical company's senior scientist. Early on, JMAR identified the pharmaceutical industry as being a high-potential market for the BioSentry. This demonstration marks a real milestone in our efforts to penetrate this complex market.